Dr. Patel on CheckMate-227 Results in Advanced NSCLC

Video

In Partnership With:

Jyoti D. Patel, MD, discusses the results of the CheckMate-227 trial, which looked at an immunotherapy combination versus chemotherapy in patients with advanced non–small cell lung cancer.

Jyoti D. Patel, MD, professor of medicine, director, Thoracic Oncology, University of Chicago Medicine, discusses the results of the CheckMate-227 trial, which looked at an immunotherapy combination versus chemotherapy in patients with advanced non—small cell lung cancer.

At the 2019 ESMO Congress, a presentation on the CheckMate-227 trial showed the comparison between nivolumab (Opdivo) and ipilimumab (Yervoy) and chemotherapy alone, explains Patel. The immunotherapy combination reached statistical significance in patients with PD-L1 tumor proportion score >1%. Patients who did not have PD-L1 expression also benefited substantially from the nivolumab/ipilimumab regimen, according to Patel.

A significant number of complete responses with the combination were observed and the toxicity was well managed. These results will benefit patients who prefer a chemotherapy-free backbone, says Patel. Next, research must determine how to select patients for the immunotherapy doublet, concludes Patel.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute